Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease

JCI Insight

Volumn 2, Issue 20, 2017, Pages

  Krishnamoorthy, Sriram ^a   Pace, Betty ^b   Gupta, Dipti ^a   Sturtevant, Sarah ^a   Li, Biaoru ^b   Makala, Levi ^b   Brittain, Julia ^c   Moore, Nancy ^a   Vieira, Benjamin F ^a   Thullen, Timothy ^d   Stone, Ivan ^d   Li, Huo ^e   Hobbs, William E ^a   Light, David R ^a  

^a Bioverativ Inc   (United States)

^b Department of Pediatrics ^*

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Preclinical Safety

^e BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041302605     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.96409     Document Type: Article

References (54)

1. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84(9):618–625.
2. Vercellotti GM, Belcher JD. Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. J Clin Invest. 2014;124(4):1462–1465.
3. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid Redox Signal. 2010;12(2):233–248.
4. Ghosh S, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809–4820.
5. Belcher JD, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377–390.
6. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276–1284.
7. Chintagari NR, Nguyen J, Belcher JD, Vercellotti GM, Alayash AI. Haptoglobin attenuates hemoglobin-induced heme oxygenase-1 in renal proximal tubule cells and kidneys of a mouse model of sickle cell disease. Blood Cells Mol Dis. 2015;54(3):302–306.
8. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med. 1980;302(18):992–995.
9. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127(7):810–819.
10. Charache S, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322.
11. Terasawa T, Ogawa M, Porter PN, Karam JD. G gamma and A gamma globin-chain biosynthesis by adult and umbilical cord blood erythropoietic bursts and reticulocytes. Blood. 1980;56(1):93–97.
12. Ogawa M, Porter PN. Fetal hemoglobin biosynthesis in clonal cell culture. Tex Rep Biol Med. 1980;40:55–65.
13. Superti-Furga G, Barberis A, Schaffner G, Busslinger M. The -117 mutation in Greek HPFH affects the binding of three nuclear factors to the CCAAT region of the gamma-globin gene. EMBO J. 1988;7(10):3099–3107.
14. Tasiopoulou M, Boussiou M, Sinopoulou K, Moraitis G, Loutradi-Anagnostou A, Karababa P. G gamma-196 C->T, A gamma-201 C->T: two novel mutations in the promoter region of the gamma-globin genes associated with nondeletional hereditary persistence of fetal hemoglobin in Greece. Blood Cells Mol Dis. 2008;40(3):320–322.
15. Toma S, Tenorio M, Oakley M, Thein SL, Clark BE. Two novel mutations (HBG1: c.-250C > T and HBG2: c.-250C > T) associated with hereditary persistence of fetal hemoglobin. Hemoglobin. 2014;38(1):67–69.
16. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014;123(4):481–485.
17. Dasgupta T, Fabry ME, Kaul DK. Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R394–R402.
18. Xu J, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 2011;334(6058):993–996.
19. Steinberg MH, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408.
20. Voskaridou E, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363.
21. Cui S, et al. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood. 2015;126(3):386–396.
22. Moutouh-de Parseval LA, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008;118(1):248–258.
23. Malhotra D, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010;38(17):5718–5734.
24. de Vooght KM, van Wijk R, Ploos van Amstel HK, van Solinge WW. Characterization of the -16C>G sequence variation in the promoters of both HBG1 and HBG2: convergent evolution of the human gamma-globin genes. Blood Cells Mol Dis. 2007;39(1):70–74.
25. Macari ER, Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood. 2011;117(22):5987–5997.
26. Viglietta V, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103–118.
27. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006;108(4):1183–1188.
28. Keleku-Lukwete N, et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc Natl Acad Sci USA. 2015;112(39):12169–12174.
29. Promsote W, et al. Monomethylfumarate induces γ-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina. Invest Ophthalmol Vis Sci. 2014;55(8):5382–5393.
30. Sheikh SI, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther. 2013;35(10):1582–1594.e9.
31. Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M. Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res. 2013;305(5):447–451.
32. Brennan MS, et al. Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms. Antioxid Redox Signal. 2016;24(18):1058–1071.
33. Billett HH, Fabry ME, Nagel RL. Hemoglobin distribution width: a rapid assessment of dense red cells in the steady state and during painful crisis in sickle cell anemia. J Lab Clin Med. 1988;112(3):339–344.
34. Belcher JD, et al. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. Antioxid Redox Signal. 2017;26(14):748–762.
35. Ngo DA, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol. 2012;156(2):259–264.
36. Zein S, et al. Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line. Exp Biol Med (May-wood). 2010;235(11):1385–1394.
37. Fabry ME, et al. Dense cells in sickle cell anemia: the effects of gene interaction. Blood. 1984;64(5):1042–1046.
38. White J, et al. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow. Br J Haematol. 2016;174(6):970–982.
39. Katsumura KR, Bresnick EH, GATA Factor Mechanisms Group. The GATA factor revolution in hematology. Blood. 2017;129(15):2092–2102.
40. Lake-Bullock H, Dailey HA. Biphasic ordered induction of heme synthesis in differentiating murine erythroleukemia cells: role of erythroid 5-aminolevulinate synthase. Mol Cell Biol. 1993;13(11):7122–7132.
41. Chen JJ. Translational control by heme-regulated eIF2α kinase during erythropoiesis. Curr Opin Hematol. 2014;21(3):172–178.
42. Katsuoka F, Yamazaki H, Yamamoto M. Small Maf deficiency recapitulates the liver phenotypes of Nrf1- and Nrf2-deficient mice. Genes Cells. 2016;21(12):1309–1319.
43. Katsuoka F, Yamamoto M. Small Maf proteins (MafF, MafG, MafK): History, structure and function. Gene. 2016;586(2):197–205.
44. Sun J, Brand M, Zenke Y, Tashiro S, Groudine M, Igarashi K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci USA. 2004;101(6):1461–1466.
45. Shan Y, Lambrecht RW, Ghaziani T, Donohue SE, Bonkovsky HL. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem. 2004;279(50):51769–51774.
46. Kalra IS, Alam MM, Choudhary PK, Pace BS. Krüppel-like Factor 4 activates HBG gene expression in primary erythroid cells. Br J Haematol. 2011;154(2):248–259.
47. Hebiguchi M, et al. Dynamics of human erythroblast enucleation. Int J Hematol. 2008;88(5):498–507.
48. Chang KH, et al. Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34(+) Hematopoietic Stem and Progenitor Cells. Mol Ther Methods Clin Dev. 2017;4:137–148.
49. van Beers EJ, et al. Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease. Am J Hematol. 2014;89(6):598–603.
50. Fertrin KY, Samsel L, van Beers EJ, Mendelsohn L, Kato GJ, McCoy JP. Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods Mol Biol. 2016;1389:279–292.
51. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
52. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
53. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
54. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289–300.